US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...

The live webcast for each event will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. Replays of the webcasts will be archived on ...

JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...

Bank of New York Mellon Corp boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 7.5% in the 4th quarter, ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.